This patient-facing factsheet explains biosimilar medicines in cancer care, describing them as highly similar alternatives to already-approved biological medicines that provide the same treatment… Read More
CPE, MEPs, and researchers call on EU policymakers to harness Real-World Evidence to improve health outcomes, regulatory decisions, and access to medicines.
Read More
PCE and partners’ position paper calls on the EU to tackle rising pancreatic cancer mortality through early detection, research funding, and equal treatment access. Read More
CPE’s EWAC 2024 Call to Action demands EU policy action on cancer prevention, diagnostics, treatment, survivorship, and smoking cessation to tackle inequalities. Read More
CPE’s EWAC 2024 webinar series report covers 5 key areas of cancer care inequality in Europe — with expert insights and calls to action for EU policymakers. Read More
CPE and CECOG call on EU institutions to pilot cancer indicators in the European Semester and develop a Cancer Inequalities Dashboard to reduce disparities in care. Read More
CPE’s new multilingual survey explores cancer patients’ awareness and access to brachytherapy across Europe. Share your experience to shape future cancer care policy. Read More
CPE highlights Lancet evidence showing excess mortality normalises before 10 years for most young cancer survivors — supporting reform of EU insurance disclosure rules. Read More
CPE’s European Parliament event report on ESR1 mutations and liquid biopsy in metastatic breast cancer — key findings, MEP statements, and policy recommendations. Read More
CPE’s 2025 White Paper reveals major awareness gaps on ESR1 mutations and liquid biopsy among metastatic breast cancer patients across 5 EU countries. Read More